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Preface
The Stanford University Cardiology Division submits this
interlm report under NASA Cooperative Agreement NCC 2-232. The
report has been requested by Technical Monitor laruld Sandler,
It. 1).,
	
Chief of the Biomedical Research Davison, 	 NASA-Ames
Research Center.
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PIIARMACOLOGIC	 COUNTERIIEASURES
FOR 1`11NIMI?.ING POST-SPACP:	 FLIGHT
011TII0STATIC	 INTOLERANCE.
Introduction
This	 interin	 report	 responds	 to	 the	 sponsors	 request	 for	 an
3
Update
	 on	 the	 status	 of	 the	 project	 Pharnacoloeic	 Countermeasures
for	 Minimizing	 Post-Space	 Flight	 Orthostatic	 Intolerance.	 There
is	 only	 limited	 pro;;ress	 to	 report	 becahlSe	 this	 project	 h.-s	 been
active	 for
	
only a
	 short	 time and	 because	 its	 formal approval	 by
the	 Institutional
	
!review	 Board	 at	 NASA-Ares	 Research	 Center	 was
delayed	 until	 January	 19133	 by	 a	 controversial	 aspect	 of	 its
protocol.
This	 project,	 however,	 is	 only one	 of	 rhany	 closely	 related
projects	 which	 comprise	 a	 productive,	 long;	 standing;	 collaborative
progyran	 with	 the	 Cardiovascular	 Research	 Laboratory	 (CVKI.)	 at
Ames.	 It	 is	 in	 the	 context	 of	 the	 overall	 collaborative	 program
that
	 the	 status	 of	 the	 current	 project	 will	 be	 reported.
Progrannat i c
	
Back,^,round
For	 nearly	 two decades
	 the	 Stanford	 University	 Cardiology
Division	 has	 been	 collaborating;	 with	 NASA-Anes	 Research	 Center	 to =
study	 the
	
cardiovascular
	 effects	 of	 spacefliht.	 The	 research
effort
	 has	 been	 focused	 in	 several	 basic
	
areas:
1.	 The	 deve1opnent,	 i^hpruvenent,
	
verification	 and
calibration	 of	 physiolo;;ic	 i n s t r u n e n t a t 1 0 n	 and
investigative
	 techniques	 to	 permit	 the	 niniina11y
invasive	 but	 (Iuant natively	 neanInpfuI	 neasurenent	 of
cardiovascular	 variables
	
in	 nan	 and	 animals
2. 13asic research to provide a better understanding of
cardiovascular physiology, the altered physiology which
night occur during and after space fligiht, and the
char.icter and rhechanisrhs of cardiovascular responses to
various types of stress
3. The development and verification of hunan and aninaI
models to facIIitate the conduct of ground - based
ca rdirhvascular research and to expand the ethically and
logistically permissable scope of suc11 research
4. Basic research to determine th(- 1)har:,hacokinetIcs of
various substances in normal and altered cardiovascular
StatCS
A
S.	 The developni!nt and irt;plenentation
nethods to automate the acquisition,
and analysis of ca rdiovaschalar data
of computer-based
stora?e, display
Am
G.	 The developuent and verificatlon of nuu-invasive methods
fur classifying	 individuals accurdin- to their
prubable susceptibility	 to potentialLy harmful
cardiovascular effects of space f light
7. The deveIi)pnent and evaluation of 	 putential
countermeasures to treat, miniinize u 	 prevent the
undesireable cardiovascular effects of spaceflight
8. The accuntilation of a body of data from ground-based
research in experimental models to he verified in future
flight experiments
The relationships among, the projects which conprise this
collaborative program are depicted on a tine line in Figure 1,
and ongoing and planned collaborative projects are listed in
Table 1.
The nature of individual projects has changed with time.
There has been a trend toward more specific definitions of
project scope and objectives as :accumulated experimental data and
flight experience have focused attention on specific issues,
problems and hypotheses. General ,?hysiologic investigations have
been replaced by studies which focus on identifying specific
mechanisms of cardiovascular deconditiuning and degeneration
during spaceflight and of post-flight orthostatic intolerance.
In the area of instrun,-^ntation and investigative methods, efforts
to develop fundamentally new technologies fur measuring;
cardiovascular variables have been replaced in part by efforts to
refine and adapt the technologies for specific, technically
denanding applications such as preflight screening;, chronic
implantation in small animals or in-flight experiments. Another
trend has been the evolution of project objectives fron simply
understanding flight-related cardiovascular physiology toward
preventing„ minimizing and treating the undesireable
cardiovascular effects of space flight.
Similar trends have characterized the sequence of projects
dealing specifically with the properties of drugs in normal and
altered cardiovascular- states. During the early 1970'x, the
emphasis was on studying; the cardiuvascular effects of drug=s in
research animal models or cardiovascular patients. Substances
studied under a broadly scoped NASA program g=rant entitled
E val ua tion o f the C ar dio v a s cu lar System D ur ing Va r i ous
C ircu la tor y S tre sse s included dopamine, Iidocaine, morphine
sulfate, digitalis glycosides, and nitroprusside, among others.
Interest in the latter half of the decade focused on studying; the
alterations in drug; disposition and elimination which could be
attributed to bedrest simulated weig=htlessness. Lidocaine,
penicillin-G and indocynine green (ICG) were studied under the
g=rant entitled The Effect of Space Flig=ht as
.
 
Simulate d by Gedrest
on Uruf, Disposition which spanned Lhe years 1973 through 1980.
2
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The current grant follows it of about two years during
which there was no project funding, to support Cardiology Division
collaboration in drug-related studies of the cardiovascular
effects of space flight.	 Although the active grant award for
this project covers it 	 beginning in September 1982, the
itwdrd was not confirmed by NASA until February 1983. The
projects foriial approval was delayed by the Institutional Review
;iu;ird at NASA-Ames Research Center due to controversy concerning,
the administration of the drug; propanolol to healthy research
subjects.	 The investigators invested substantial effort in
resolving, the Iah controversy and in preparing; for the study in
anticipation of the award. Reportable progress is limited,
however, because this project has been truly active for only a
short period of time.
Progress
In r r d e r to present tlie	 project in perspective, this
progress report will cover a period beoinnin in 1980, incltiding
the two year period during which there was no funding to support
collaboration in drug-related studies.
D rug disposition.	 Two groups of subjects were studied to
determine the effect of bedrest on drug disposition and
physiologic function.	 The first group was studied at the
Stanford Clinical Research Center and consisted of twelve healthy
male volunteers between the ages of 45 and 55 years. Each
individual was administered an intravenous dose of lidocaine,
penecillin-C and ICG during a control period and following;
seven days of bedrest in order to determine the effect of
prolonged recumbency on drug disposition. In addition, cardiac
function was evaluated before and seven days after bedrest by
echocardioraphy.
A second group of subjects consisting of healthy, normal
male volunteers between the ages of 55 and 65 years was studied
at the NASA-Ames facility. 	 Renal function was evaluated before
and after several days of bedrest. Inulin, para-aminohippurate
and dextran clearances were evaluated during; a constant Infusion
protocol.
Results of the study in the first group are summarized in
Tables 2 through 4.	 In six of the subjects, ICC clearance a
decreased slightly after seven days. In the other six
individi ► als, ICC clearance was observed to be somewhat increased.
It was found that the half-life, the clearance and the volume of
distribution of lidocaine were not affected by seven days of
bed rest
	
The pre- and post-bed rest values for half-life,g
clearance and volume of distribution were 1.73 + 0.24 and 1.79 +
0.41 hours for the half -life and 4.59 + 0.67 and 4.67 + 0.69
ml/min/kg For clearance and 0.6E + 0.13 and 0.70 + 0.10 1/kg for
the volume of distribution. In non-of these crises was the post-
bed rest paraneter statistically different from the pre-bedrest
value.
3
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Penicillin is almost total ly eliminated by renal function
it A therefore penicillin clearance provides it 	 estimate of
renal function.
	
In this study it appeared that renal function
did not change sign if icantly of ter seven days of bed rest. 	 As
above, the half -life , clearance and volume of distribution were
calculated.
	
The half-life pre- and post-bed rest was 49.2 + 6.4
min and 51.2 + 9.1 min.
	 The clearances were 7.0 + 1.6 and 7.4 +
1.9 ml/nin/kg; and the volume of distribution terms were 0.49 +
0.1 and 0.53 + 0.1 1/k,;.
	 There were no statistically si-nificant
changes pre- and post-bed rest.	 These results have been
published (Kates RF., ilarapat SR, Keefe DLD, Col ,iwater U, Ilarrison
1)C: Influence of prolonged recumhency oil drug; disposition. Clin.
Pharmcol. Therap. 28:624-628, 1980)
Resting; heart rate, end diastolic volume and systolic volune
were all significantly changed, but cardiac output and ejection
fraction were not significantly altered by bed rest.
In the second grout, renal function was evaluated with
Inulin, para-at riinohippurate and dextran.	 As indicated by the
results summarized in Table 5, no changes were observed following;
seven days of bed rest.
Protocol development.	 Two relevant protocols were developed
during; this period.
	
Funding could not be obtained for the first
protocol, which had two objectives: to examine the early effects
of bedrest oil disposition and elimination of propanolol and
to examine the effects of menstrual cycle variability on the
disposition and elimination of prupanolol in females. The second
protocol which was developed governs the conduct of the present
project.
St tic; Ies unclerw_^. 	 The studies which were planned for this
project have been courdinated with another collaborative study
which is just underway at the Veterans Administration hospital, a
part of the Stanford University Medical Center complex. Twenty
normal volunteers have been recruited to undergo cardiovascular
deconditiong by water immersion and six-degree head down bedrest.
The coordinate protocol includes pre- and post-deconditioning
analyses of re:nins and catecholamines,	 pre- and post -
deconditioninp echocardiographic examination and propanolol
challenges at the end of the deconditioning; period.
Plans
The purpose of this project is to examine a potential
pharmacolo,^,ic countermeasure for preventing or minimLzi.ng
orthostatic intolerance following; space flight and, in so doing„
also to investigate the underlying raechantsms which produce this
state.	 The working; hypothesis is 	 that beta adrenergic blockade
alone or in combination with an antitnuscarinic agent is an
eftective countermeasure for post-flight orthostatic hypotension,
which has been observed frequently in previous prolonged space
flights.	 The project addresses the following specific questions:
aJ
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1. ltihat is thr relationship between close, or plasma level,
of 1)ro1)ranoIol and the change in heart rate, 1)1asna
ren1n activity and left ventricular functio' ► <lurin
LKGP?
2. llhat is the relationship between dose, plasma level, of
atro, ine and chani;e in heart rate and left ventricular
f ►► nction during 1,I;rN?
3. Are there differences between men and woven, athletes
and non-athletes in regard to their dose response curves
for prupranolol and the combination of atropine plus
1)ro1)ranulo1?
4. What is the optimal dosage cor► bination for prevent in11
orthos tat ic intolerance in these groups of subjects?
Uork ► •g ill. cuntLnue with the water immersion studies just
beginning at Stanford and G - degree head down bedrest studies
beginning at Anes this sunnier. At Stanford, healthy middle-aged
volunteers and volunteers with mild hypertension will undergo
six hours of water immersion followed by overnight bed rest.
After this exposure subjects will be given a two hour stand test
during which nenruendocrine studies will be dune and
cardiovascular responses will be monitored by echocardiography.
Control subjects will receive no nedication prier to the stand
te..t while a matched ;roue of subjects each will receive 60 rig,
p.o. propanolol as a pharmalogical countermeasure for orthostatic
intolerance.
During the sunnier at Ames, healthy men aged 35 to 50, half
of whom will be endurance trained athletes, will be tested for
orthostatic	 intolerance	 using	 tI ► ree pharmacologic
counterr ► easures.	 Two of the dru,;s, propranolol and atropine, are
describes; in Figure 2. 	 The third drug, phenylephrine, is a
direct alpha adrenergic sti p ulator of vasoconstriction. It is
anticipated that aerobically conditioned subjects with hi,-,h
levels of vagal tone will respond particularly well to atropine.
This subgroup, which is especially prone to early syncope, is
fairly representative of the current astronaut population.
The results f r o n these studies will help to reveal the
nechanis ►:is .4hich underIv ca rdiovascuIar de conditionin- and to
foster development of safe, efficient and specific pharmacoLog,ic
counterneasures t a i I u r e d to the individual pItysioIo?,ic
characteristics of each nem'uer of a flight crew.
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FIGURE 1: Collaborative Projects in the Cardiovascular effects of Spaceflight; 4It indicates the project for 
which this report is submitted. 
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Table 1
On going it rid planned collaborative projects
Development of Ultrasonic Indices for Space Shuttle
Passenger Selection (14CC 2-1 and proposed for
continuation)
;affects of Simulated Weightlessness on Regional
Rloodflow Specifically During; Cardiovascular Stress
(NCC 2-126)
:actors Influencing; 0rt1iostatic and Re-entry
Intolerance Following; tie ig;htlessness Siriulation
(,CA2-OR745 -108 )
Pharmacolog;ic Countermeasures for Mini.rii.zing Post-
Space Flight orthos tit Lic Intolerance (NCC 2 -232;
continuation pruposals planned)
The Rule of Atrial Volune Recepturs in the
Regulation of body Fluids in Ilan (Proposed)
Hyperadrener;;ic States and the hole of Receptor
Regulation in the Cardiovascular Effects of
i le.ig;htlessness (Proposal in Preparation)
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Table 2
ICC Data
(e,,/i:a) (m;;/ ► . ► 1-r:iu) (w.t/ ►a1.tt/k^) (n]A- )
16.24 72.2.('1, 6.92 30.8
13 . fi t G	 .`c S 7.4 t; 33.4
11.60 85.73 13.31 43.1
16.11 84.55 5.91 31.0
9.78 52.89 9.45 •51.1
1'..06 74.13 6.74 35.6
10.16 G,.6^ 7.74 49.2
11.36 62.61 7.99 44.0
11 . S1 97.11 5.1.5 424.3
14 . "1 79. On 6.1.1 33.5
16.03 T/. 	 7 6.48 31.2
13.94 72.78 6.05 31.6
9.125 58.1.0 0.61 54.8
5.613 39.81 12.56 89.1
9.23 32.77 14.04 49.8
7.61 45.99 10.00 60.4
26.61 73.77 6.78 18.8
11.94 87.77 5.70 41.9
'10 . ri^ 69.35 7.21 74.3
17.77 96.70 5.17 28.1
8.57 + 2.94
7.39 + 2.29
NS 39.5	 •1-	 I?. 
43.4	 •!-	 15.
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Table 3
Lidnc: ► ine Data
St:; ► j «^ il::l f-3 1 f	 (It r.,;)
1 1.73 1.79
1 1.92
.
2.69
3 1.43 1.43
4 1.65 1.11E
1.4G 1.50
is 1. 64 1.80
7 1.85 1.65
2.16 1.95
..in 3.73 1.79
Sit ±0.21, ±0.41
NS
Vd CL	 S► 1'^' ^c:r: t Pre Pos t
3.wi 4.36 0.59
4. 2.1 3.79
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I
j
5.10 14.00 0.72 0.62
3.58 t► .14 0.57 0.59'.S9
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Table 4
i
I'CI ► iCtIIiI1 t)i,Ca
C) r: ► rwicu
( ►n1/r in/k,g)
pre	 post
5.2	 7.8
7.9	 8.2
9.2	 10.6
7.4
	
8.6
9.6	 9.7
6.8	 7.8
6.9	 7.6
7.0	 8.9
5.3	 4.6
8.5	 6.9
5.1	 5.3
5.5	 4.7.
	
7.0	 7.4
1.6 a 1.9
	
0.5
	
0.5
Vs
VC1 (;,/I :,.)
pre	 p.!. +r
0.3;'	 0.55
0.49	 0.67
0.68	 0.68
0.46	 0.49
0.56	 0.59
0.37	 0.48
0.55	 0.54
0.55	 0.55
0.40	 0.41
0.60	 0.63
0.39	 0.40
0.47	 0.40
0.49	 0 53
0..10
	
0.10
0.01	 0.03
nS
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0
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Table 5
.Renal Function Studies Before and
.During Bed Rest in SS to 65 year old Male Volunteers
Subj act Glomerular(m),/min)
Filtration Rate
Renal Blood flow
(ml/min)
F. Itration
Yraction
Pre Post Pre Post Pro post
1 92.6 98.2 822.2 1064.5 0.24 0.20
2 - - - - .0.21 0.77
3 121.8 82.7 755.E 782.8 0.32 0.2:
4 110.3 79.0 1209.b 10'16.1 0.17 0.15
5 72.3 78.8 738.3 826.9 0.20 0.19
6 68.5 89.1 754.2 850.6 0.18 0.22
7 114.0 125.2 1104.3 1321.0 0.21 0.19
8 86.5 84.4 785.1 752.7 0.23 0.23
Mean
± SD 95.1 91.0 881.2 948.5 0.22 0.20
20.9 16.5 192.8 203.4 0.047 0.025
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